Biomea Fusion said new clinical data suggest icovamenib maintained HbA1c improvement after a 12-week treatment period. The durability signal could matter for di

Biomea Fusion said new clinical data suggest icovamenib maintained HbA1c improvement after a 12-week treatment period. The durability signal could matter for diabetes management as the investigational therapy advances through Phase II studies.